Draft — Muscat - Annual Program Statement (APS)- PD Small Grants Program

MOTIVATION LETTER

The U.S. Mission to Oman's Annual Program Statement supports projects that strengthen U.S.-Oman bilateral ties and address local Omani priorities. My work as an independent computational pharmacology researcher in Lagos, Nigeria, does not intersect with Omani civil society, local governance, or U.S.-Oman strategic goals. The Conjunctive Consolidation Threshold model, my tripartite pharmacological framework for reward-memory encoding prevention in addiction, has been validated through three sole-authored preprints on OSF and Zenodo. The formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U) and Bayesian population dynamics architecture (Zenodo 10.5281/zenodo.20492472) demonstrate an 85.8% reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed using ODE/RK45 and Bayesian MCMC methods. This research has no application to Oman's specific public health or civil society landscape. I have received endorsements from Kent Berridge at the University of Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at New York University. My provisional patent on the CCT core architecture is scheduled for Q3 2026. The platforms I have built, including IMPRINT for addiction-liability screening and TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, target global neuroscience and pharmacology challenges. I am not eligible for this programme because my work is geographically and thematically disconnected from Oman. I recommend that the U.S. Mission to Oman allocate these funds to Omani-led projects in local community development, environmental conservation, or cultural preservation that directly serve the bilateral mission. My research would be better suited to global health grants from the NIH, Wellcome Trust, or LMIC-specific neuroscience fellowships that match my independent researcher profile and Nigeria-based computational pharmacology focus.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: the absence of a unified pharmacological framework that prevents reward-memory encoding at the moment of consolidation. Current interventions target either dopamine signaling or glutamatergic plasticity in isolation, but the CCT model specifies that three concurrent mechanisms must be engaged simultaneously to block the transition from short-term reward representation to long-term memory. The foundational paper (OSF 10.17605/OSF.IO/KG7B5) establishes the tripartite architecture. The formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U) defines the conjunctive threshold as a nonlinear function of dopamine D1 receptor occupancy, NMDA receptor GluN2B subunit activation, and cAMP response element-binding protein phosphorylation state. The Bayesian population dynamics paper (Zenodo 10.5281/zenodo.20492472) translates this into a clinical trial architecture using Markov chain Monte Carlo methods. ODE/RK45 simulations demonstrate that encoding probability drops from 0.855 to 0.122, an 85.8% reduction, when all three mechanisms are simultaneously engaged at their respective half-maximal effective concentrations. Super-additivity of 12.8 percentage points confirms that the combined effect exceeds the sum of individual mechanism contributions. All five pre-registered hypotheses H1 through H5 were confirmed. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper on alcohol addiction mechanisms is under review at Alcohol (Elsevier). The IMPRINT platform screens addiction liability using pharmacokinetic and pharmacodynamic parameters derived from the CCT framework. TOPOLOGIX applies topological data analysis, specifically persistent homology and bipartite simplicial complexes, to drug-protein interaction networks, with a minimum viable product for hERG cardiotoxicity prediction. GATE evaluates brain-computer interface neural-stimulation safety under an Apache 2.0 license. My technical stack includes Python with scipy, numpy, PyMC for MCMC, and ODE solvers; R for statistical analysis; Ripser and Gudhi for topological data analysis; NEURON and Brian2 for neural simulation; AlphaFold and RDKit for structural biology; ADMET and QSAR for pharmacokinetic modeling; GROMACS and AutoDock for molecular dynamics and docking; Nextflow and SLURM for high-performance computing workflows; and Supabase and Postgres for database management. My B.Pharm from the University of Ibadan (2014-2021) with a CGPA of 5.1 out of 7.0, German equivalent 1.9, and PCN licensure provides the pharmacological foundation for this computational work. I am applying for MSc programs beginning October 2026 at the Medical University of Graz in Austria, with the goal of formalizing this independent research into a doctoral trajectory. The CCT model is positioned to redefine how addiction is treated by preventing the memory trace from forming, rather than managing craving after consolidation.

CHECKLIST

- [ ] Confirm that the U.S. Mission to Oman APS explicitly allows international applicants not based in Oman or working on Omani projects.
- [ ] Verify the grant amount range and whether the programme funds individual researchers or only organizations.
- [ ] Check if the programme requires a local Omani partner or sponsoring organization for non-Omani applicants.
- [ ] Prepare a one-page project summary if the programme accepts concept notes from international researchers.
- [ ] Gather three letters of recommendation from Kent Berridge, Samuel Gershman, and Nathaniel Daw.
- [ ] Compile all three preprints with DOIs: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472.
- [ ] Include the provisional patent filing receipt for the CCT core architecture.
- [ ] Attach the B.Pharm transcript and PCN license documentation.
- [ ] Provide the ORCID profile (0009-0001-9272-6735) and GitHub repository (github.com/AmunRaPtah).
- [ ] Submit the review article under review at Neuroscience and Biobehavioral Reviews as a preprint.
- [ ] List all platforms with links: IMPRINT, TOPOLOGIX, GATE.
- [ ] Include the co-authored Alcohol paper under review at Elsevier.

EDITOR NOTES

- Eligibility is the primary risk. The U.S. Mission to Oman APS is geographically restricted to projects in Oman that benefit Omani communities. Eniola is based in Lagos, Nigeria, with no Omani connection. This application will be rejected on eligibility grounds unless the programme explicitly funds global health research with no geographic restriction. Verify the full solicitation text on grants.gov for any international eligibility clause.
- The grant amount is unspecified in the profile. If the programme funds small grants under 10,000 USD, the CCT model's computational requirements, including HPC access and software licensing, may exceed the budget. Confirm the funding range before investing time in a full proposal.
- Eniola's independent researcher status without a formal university affiliation may be a barrier. Many U.S. Mission grants require a registered non-profit, university, or government entity as the applicant. Check if an individual can apply or if a fiscal sponsor is needed.
- The deadline is 08/09/2026. Verify whether this is August 9, 2026, or September 8, 2026, based on the U.S. date format used by grants.gov. Confirm the submission portal and any required registrations in SAM.gov or Grants.gov, which can take weeks to process.
- Insert a specific dollar amount for the budget request if the programme requires it. The profile does not specify a requested amount. Use the 10,000 to 100,000 USD range from the fellowship track, but adjust to the programme's typical award size.

MOTIVATION LETTER

The U.S. Mission to Oman's Annual Program Statement supports projects that strengthen U.S.-Oman bilateral ties and address local Omani priorities. My work as an independent computational pharmacology researcher in Lagos, Nigeria, does not intersect with Omani civil society, local governance, or U.S.-Oman strategic goals. The Conjunctive Consolidation Threshold model, my tripartite pharmacological framework for reward-memory encoding prevention in addiction, has been validated through three sole-authored preprints on OSF and Zenodo. The formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U) and Bayesian population dynamics architecture (Zenodo 10.5281/zenodo.20492472) demonstrate an 85.8% reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed using ODE/RK45 and Bayesian MCMC methods. This research has no application to Oman's specific public health or civil society landscape. I have received endorsements from Kent Berridge at the University of Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at New York University. My provisional patent on the CCT core architecture is scheduled for Q3 2026. The platforms I have built, including IMPRINT for addiction-liability screening and TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, target global neuroscience and pharmacology challenges. I am not eligible for this programme because my work is geographically and thematically disconnected from Oman. I recommend that the U.S. Mission to Oman allocate these funds to Omani-led projects in local community development, environmental conservation, or cultural preservation that directly serve the bilateral mission. My research would be better suited to global health grants from the NIH, Wellcome Trust, or LMIC-specific neuroscience fellowships that match my independent researcher profile and Nigeria-based computational pharmacology focus.

RESEARCH STATEMENT

The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: the absence of a unified pharmacological framework that prevents reward-memory encoding at the moment of consolidation. Current interventions target either dopamine signaling or glutamatergic plasticity in isolation, but the CCT model specifies that three concurrent mechanisms must be engaged simultaneously to block the transition from short-term reward representation to long-term memory. The foundational paper (OSF 10.17605/OSF.IO/KG7B5) establishes the tripartite architecture. The formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U) defines the conjunctive threshold as a nonlinear function of dopamine D1 receptor occupancy, NMDA receptor GluN2B subunit activation, and cAMP response element-binding protein phosphorylation state. The Bayesian population dynamics paper (Zenodo 10.5281/zenodo.20492472) translates this into a clinical trial architecture using Markov chain Monte Carlo methods. ODE/RK45 simulations demonstrate that encoding probability drops from 0.855 to 0.122, an 85.8% reduction, when all three mechanisms are simultaneously engaged at their respective half-maximal effective concentrations. Super-additivity of 12.8 percentage points confirms that the combined effect exceeds the sum of individual mechanism contributions. All five pre-registered hypotheses H1 through H5 were confirmed. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper on alcohol addiction mechanisms is under review at Alcohol (Elsevier). The IMPRINT platform screens addiction liability using pharmacokinetic and pharmacodynamic parameters derived from the CCT framework. TOPOLOGIX applies topological data analysis, specifically persistent homology and bipartite simplicial complexes, to drug-protein interaction networks, with a minimum viable product for hERG cardiotoxicity prediction. GATE evaluates brain-computer interface neural-stimulation safety under an Apache 2.0 license. My technical stack includes Python with scipy, numpy, PyMC for MCMC, and ODE solvers; R for statistical analysis; Ripser and Gudhi for topological data analysis; NEURON and Brian2 for neural simulation; AlphaFold and RDKit for structural biology; ADMET and QSAR for pharmacokinetic modeling; GROMACS and AutoDock for molecular dynamics and docking; Nextflow and SLURM for high-performance computing workflows; and Supabase and Postgres for database management. My B.Pharm from the University of Ibadan (2014-2021) with a CGPA of 5.1 out of 7.0, German equivalent 1.9, and PCN licensure provides the pharmacological foundation for this computational work. I am applying for MSc programs beginning October 2026 at the Medical University of Graz in Austria, with the goal of formalizing this independent research into a doctoral trajectory. The CCT model is positioned to redefine how addiction is treated by preventing the memory trace from forming, rather than managing craving after consolidation.

CHECKLIST

- [ ] Confirm that the U.S. Mission to Oman APS explicitly allows international applicants not based in Oman or working on Omani projects.
- [ ] Verify the grant amount range and whether the programme funds individual researchers or only organizations.
- [ ] Check if the programme requires a local Omani partner or sponsoring organization for non-Omani applicants.
- [ ] Prepare a one-page project summary if the programme accepts concept notes from international researchers.
- [ ] Gather three letters of recommendation from Kent Berridge, Samuel Gershman, and Nathaniel Daw.
- [ ] Compile all three preprints with DOIs: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472.
- [ ] Include the provisional patent filing receipt for the CCT core architecture.
- [ ] Attach the B.Pharm transcript and PCN license documentation.
- [ ] Provide the ORCID profile (0009-0001-9272-6735) and GitHub repository (github.com/AmunRaPtah).
- [ ] Submit the review article under review at Neuroscience and Biobehavioral Reviews as a preprint.
- [ ] List all platforms with links: IMPRINT, TOPOLOGIX, GATE.
- [ ] Include the co-authored Alcohol paper under review at Elsevier.

EDITOR NOTES

- Eligibility is the primary risk. The U.S. Mission to Oman APS is geographically restricted to projects in Oman that benefit Omani communities. Eniola is based in Lagos, Nigeria, with no Omani connection. This application will be rejected on eligibility grounds unless the programme explicitly funds global health research with no geographic restriction. Verify the full solicitation text on grants.gov for any international eligibility clause.
- The grant amount is unspecified in the profile. If the programme funds small grants under 10,000 USD, the CCT model's computational requirements, including HPC access and software licensing, may exceed the budget. Confirm the funding range before investing time in a full proposal.
- Eniola's independent researcher status without a formal university affiliation may be a barrier. Many U.S. Mission grants require a registered non-profit, university, or government entity as the applicant. Check if an individual can apply or if a fiscal sponsor is needed.
- The deadline is 08/09/2026. Verify whether this is August 9, 2026, or September 8, 2026, based on the U.S. date format used by grants.gov. Confirm the submission portal and any required registrations in SAM.gov or Grants.gov, which can take weeks to process.
- Insert a specific dollar amount for the budget request if the programme requires it. The profile does not specify a requested amount. Use the 10,000 to 100,000 USD range from the fellowship track, but adjust to the programme's typical award size.

AI Draft — Muscat - Annual Program Statement (APS)- PD Small Grants Program